-
ENDRA reports feasibility study shows liver fat measurement device accuracy
-
ENDRA Life Sciences (NDRA) Misses Q3 EPS by 210c
-
ENDRA Life Sciences begins staking HYPE digital assets with partners
-
ENDRA Life Sciences (NDRA) Misses Q2 EPS by 171c
-
ENDRA Life Sciences (NDRA) to develop and pursue a cryptocurrency treasury strategy
-
ENDRA Life Sciences (NDRA) Files for 15.7M Share and Warrant Offering
-
ENDRA Life Sciences (NDRA) Misses Q1 EPS by 186c
-
ENDRA Life Sciences (NDRA) Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
-
ENDRA Life Sciences (NDRA) Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
ENDRA Life Sciences (NDRA) Granted Extension to Regain Nasdaq Compliance
-
ENDRA Life Sciences (NDRA) Misses Q2 EPS by 8c
-
ENDRA Life Sciences (NDRA) Announces Reverse Stock Split
-
ENDRA Life Sciences (NDRA) Announces Leadership Changes

